Perspective Therapeutics Inc. (CATX)vsDexCom Inc (DXCM)
CATX
Perspective Therapeutics Inc.
$2.94
-2.00%
HEALTHCARE · Cap: $336.44M
DXCM
DexCom Inc
$82.66
-4.92%
HEALTHCARE · Cap: $31.49B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 803978% more annual revenue ($4.97B vs $618,000). DXCM leads profitability with a 20.1% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 72/100 (B).
CATX
Avoid30
out of 100
Grade: F
DXCM
Strong Buy72
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Every $100 of equity generates 31 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 11.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CATX
The strongest argument for CATX centers on Price/Book, Debt/Equity.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : CATX
The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.
Bear Case : DXCM
The primary concerns for DXCM are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
CATX profiles as a value stock while DXCM is a mature play — different risk/reward profiles.
CATX carries more volatility with a beta of 1.75 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 30/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Perspective Therapeutics Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.
Visit Website →DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?